Literature DB >> 9266128

Joint destruction in rheumatoid arthritis: biological bases.

G Kingsley1, G S Panayi.   

Abstract

The pathogenesis of rheumatoid arthritis (RA) can be explained through two main hypotheses: macrophage-fibroblast and macrophage-T cell interactions. The interplay between the various populations is influenced by a strong genetic component, which determines the severity of the disease in some cohorts of patients attending referral centers. The key question of the nature of the antigen(s) driving joint inflammation still remains unsolved. Exogenous antigens such as viruses or bacteria have long been searched for in the synovial fluids as well as in tissues, but convincing evidence of their pathogenic role are lacking. Data have been accumulated on the possible role of autoantigens, such as the spliceosomes, filaggrin, calpastatin, type II collagens, or other endogenous peptides, but no definite role regarding their potential contribution to the activation of T cells has been established. Once the process starts, a progressive recruitment of inflammatory T cells and macrophages into the joints occurs through a complex series of adhesion and migratory events. The key driving steps leading to synovial inflammation and cartilage destruction, along with the potential contribution of some key molecules, have been described, thus opening possible perspectives for a therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266128

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

Review 1.  Production of interleukin-6 by synovial fibroblasts in rheumatoid arthritis.

Authors:  H Baumann; I Kushner
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

2.  IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding.

Authors:  S G Hymowitz; E H Filvaroff; J P Yin; J Lee; L Cai; P Risser; M Maruoka; W Mao; J Foster; R F Kelley; G Pan; A L Gurney; A M de Vos; M A Starovasnik
Journal:  EMBO J       Date:  2001-10-01       Impact factor: 11.598

Review 3.  Etanercept: a review of its use in rheumatoid arthritis.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

4.  Role of pGlu-serpinin, a novel chromogranin A-derived peptide in inhibition of cell death.

Authors:  Hisatsugu Koshimizu; Niamh X Cawley; Alfred L Yergy; Y Peng Loh
Journal:  J Mol Neurosci       Date:  2011-05-03       Impact factor: 3.444

5.  Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis.

Authors:  L Paimela; T Palosuo; K Aho; M Lukka; P Kurki; M Leirisalo-Repo; R von Essen
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

6.  The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis.

Authors:  Jennifer M McCoy; Joan R Wicks; Laurent P Audoly
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

7.  Presence of Mycoplasma fermentans in the bloodstream of Mexican patients with rheumatoid arthritis and IgM and IgG antibodies against whole microorganism.

Authors:  Constantino Gil; Antonio Rivera; David Bañuelos; Salvador Salinas; Ethel García-Latorre; Lilia Cedillo
Journal:  BMC Musculoskelet Disord       Date:  2009-08-03       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.